124 related articles for article (PubMed ID: 36522269)
1. Distinct Profiles of DNA Repair Activity Define Favorable-risk Prostate Cancer Subtypes With Divergent Outcome.
Swami N; Nguyen T; Ogobuiro I; Abramowitz M; Chipidza F; Davicioni E; Meiyappan K; Pra AD; Nguyen PL; Pollack A; Punnen S; Mahal BA; Alshalalfa M
Clin Genitourin Cancer; 2023 Feb; 21(1):76-83. PubMed ID: 36522269
[TBL] [Abstract][Full Text] [Related]
2. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
3. The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer.
Cooperberg MR; Erho N; Chan JM; Feng FY; Fishbane N; Zhao SG; Simko JP; Cowan JE; Lehrer J; Alshalalfa M; Kolisnik T; Chelliserry J; Margrave J; Aranes M; Plessis MD; Buerki C; Tenggara I; Davicioni E; Carroll PR
Eur Urol; 2018 Oct; 74(4):444-452. PubMed ID: 29853306
[TBL] [Abstract][Full Text] [Related]
4. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.
Preisser F; Chun FKH; Pompe RS; Heinze A; Salomon G; Graefen M; Huland H; Tilki D
Eur Urol; 2019 Jul; 76(1):106-114. PubMed ID: 30772034
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients.
Zhang D; Xu X; Wei Y; Chen X; Li G; Lu Z; Zhang X; Ren X; Wang S; Qin C
Cancer Control; 2022; 29():10732748221129451. PubMed ID: 36283420
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
Giesing M; Suchy B; Driesel G; Molitor D
BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
[TBL] [Abstract][Full Text] [Related]
7. Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer.
Kishan AU; Romero T; Alshalalfa M; Liu Y; Tran PT; Nickols NG; Ye H; Sajed D; Rettig MB; Reiter RE; Garraway IP; Spratt DE; Freedland SJ; Zhao X; Li Z; Deek M; Livingstone J; Mahal BA; Nguyen PL; Feng FY; Den RB; Schaeffer EM; Lotan TL; Karnes RJ; Klein EA; Ross AE; Grogan T; Davicioni E; Elashoff D; Boutros PC; Weidhaas JB
Eur Urol; 2020 Sep; 78(3):327-332. PubMed ID: 32461072
[TBL] [Abstract][Full Text] [Related]
8. Oncologic outcomes of organ-confined Gleason grade group 4-5 prostate cancer after radical prostatectomy.
Preisser F; Wang N; Abrams-Pompe RS; Chun FK; Graefen M; Huland H; Tilki D
Urol Oncol; 2022 Apr; 40(4):161.e9-161.e14. PubMed ID: 34973856
[TBL] [Abstract][Full Text] [Related]
9. Chromosome 8q arm overexpression is associated with worse prostate cancer prognosis.
Alshalalfa M; Nguyen TT; Stopsack KH; Khan A; Franco I; Seldon C; Swami N; Jin W; Meiyappan K; Ton M; Venstrom JM; Dee EC; Mahal BA
Urol Oncol; 2023 Feb; 41(2):106.e17-106.e23. PubMed ID: 36400666
[TBL] [Abstract][Full Text] [Related]
10. Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.
van der Doelen MJ; Isaacsson Velho P; Slootbeek PHJ; Pamidimarri Naga S; Bormann M; van Helvert S; Kroeze LI; van Oort IM; Gerritsen WR; Antonarakis ES; Mehra N
Eur J Cancer; 2020 Sep; 136():16-24. PubMed ID: 32634759
[TBL] [Abstract][Full Text] [Related]
11. Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects.
Aldea M; Lam L; Orillard E; Llacer Perez C; Saint-Ghislain M; Gravis G; Fléchon A; Roubaud G; Barthelemy P; Ricci F; Priou F; Neviere Z; Beaufils M; Laguerre B; Hardy AC; Helissey C; Ratta R; Borchiellini D; Pobel C; Joly F; Castro E; Thiery-Vuillemin A; Baciarello G; Fizazi K
Eur J Cancer; 2021 Dec; 159():87-97. PubMed ID: 34742160
[TBL] [Abstract][Full Text] [Related]
12. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
[TBL] [Abstract][Full Text] [Related]
13. The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance.
Kato M; Hirakawa A; Kobayashi Y; Yamamoto A; Ishida R; Sano T; Kimura T; Majima T; Ishida S; Funahashi Y; Sassa N; Fujita T; Matsukawa Y; Yamamoto T; Hattori R; Gotoh M; Tsuzuki T
Prostate; 2019 Jul; 79(10):1065-1070. PubMed ID: 31025722
[TBL] [Abstract][Full Text] [Related]
14. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
15. Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit.
Radtke JP; Takhar M; Bonekamp D; Kesch C; Erho N; du Plessis M; Buerki C; Ong K; Davicioni E; Hohenfellner M; Hadaschik BA
Eur Urol Focus; 2018 Jul; 4(4):540-546. PubMed ID: 28753844
[TBL] [Abstract][Full Text] [Related]
16. Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.
Spratt DE; Dai DLY; Den RB; Troncoso P; Yousefi K; Ross AE; Schaeffer EM; Haddad Z; Davicioni E; Mehra R; Morgan TM; Rayford W; Abdollah F; Trabulsi E; Achim M; Tapia ELN; Guerrero M; Karnes RJ; Dicker AP; Hurwitz MA; Nguyen PL; Feng FFY; Freedland SJ; Davis JW
Eur Urol; 2018 Jul; 74(1):107-114. PubMed ID: 29233664
[TBL] [Abstract][Full Text] [Related]
17. Identification of DNA Damage Repair-Associated Prognostic Biomarkers for Prostate Cancer Using Transcriptomic Data Analysis.
Teng PC; Huang SP; Liu CH; Lin TY; Cho YC; Lai YL; Wang SC; Yeh HC; Chuu CP; Chen DN; Cheng WC; Li CY
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769200
[TBL] [Abstract][Full Text] [Related]
18. DNA damage response and prostate cancer: defects, regulation and therapeutic implications.
Karanika S; Karantanos T; Li L; Corn PG; Thompson TC
Oncogene; 2015 May; 34(22):2815-22. PubMed ID: 25132269
[TBL] [Abstract][Full Text] [Related]
19. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.
Pierorazio PM; Ross AE; Lin BM; Epstein JI; Han M; Walsh PC; Partin AW; Pavlovich CP; Schaeffer EM
BJU Int; 2012 Oct; 110(8):1122-8. PubMed ID: 22373045
[TBL] [Abstract][Full Text] [Related]
20. Oncologic outcome of radical prostatectomy versus radiotherapy as primary treatment for high and very high risk localized prostate cancer.
Emam A; Hermann G; Attwood K; Ji W; James G; Kuettel M; Mohler JL
Prostate; 2021 Mar; 81(4):223-230. PubMed ID: 33471385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]